Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in Int J Urol

Retrieve available abstracts of 101 articles:
HTML format



Single Articles


    July 2022
  1. KIMURA K, Kitajima K, Kawanaka Y, Yokoyama H, et al
    Evaluation of (11) C-choline positron emission tomography/computed tomography for determining treatment response in castration-resistant prostate cancer patients.
    Int J Urol. 2022 Jul 25. doi: 10.1111/iju.14992.
    PubMed     Abstract available


  2. KATO T, Yokomizo A, Matsumoto R, Tohi Y, et al
    Comparison of the medical costs between active surveillance and other treatments for early prostate cancer in Japan using data from the PRIAS-JAPAN study.
    Int J Urol. 2022 Jul 19. doi: 10.1111/iju.14977.
    PubMed     Abstract available


    June 2022
  3. KASHIWAGI E, Shiota M, Naganuma H, Monji K, et al
    Testosterone level in seminal vesicle fluid is a better indicator of erectile function than serum testosterone in patients with prostate cancer.
    Int J Urol. 2022 Jun 18. doi: 10.1111/iju.14953.
    PubMed     Abstract available


  4. KONISHI T, Washino S, Okochi T, Miyagawa T, et al
    Combination of biparametric magnetic resonance imaging with prostate-specific antigen density to stratify the risk of significant prostate cancer: Initial biopsy and long-term follow-up results.
    Int J Urol. 2022 Jun 13. doi: 10.1111/iju.14948.
    PubMed     Abstract available


    May 2022
  5. NARITA S, Terada N, Nomura K, Sakamoto S, et al
    Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy.
    Int J Urol. 2022 May 25. doi: 10.1111/iju.14938.
    PubMed     Abstract available


  6. BANNO T, Nakamura K, Kaneda Y, Ozaki A, et al
    Detection rate and variables associated with incidental prostate cancer by holmium laser enucleation of the prostate.
    Int J Urol. 2022 May 18. doi: 10.1111/iju.14917.
    PubMed     Abstract available


  7. SEKITO T, Sadahira T
    Editorial Comment to Detection rate and variables associated with incidental prostate cancer by holmium laser enucleation of the prostate.
    Int J Urol. 2022 May 18. doi: 10.1111/iju.14934.
    PubMed    


  8. TAVERNA G, Grizzi F, Tidu L, Bax C, et al
    Accuracy of a new electronic nose for prostate cancer diagnosis in urine samples.
    Int J Urol. 2022 May 9. doi: 10.1111/iju.14912.
    PubMed     Abstract available


    April 2022
  9. FUJITA K, Matsushita M, Banno E, De Velasco MA, et al
    Gut microbiome and prostate cancer.
    Int J Urol. 2022 Apr 6. doi: 10.1111/iju.14894.
    PubMed     Abstract available


  10. ZANG Z, Wang Z, Chiong E
    Editorial Comment to Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-c
    Int J Urol. 2022 Apr 5. doi: 10.1111/iju.14891.
    PubMed    


  11. KATO M
    Editorial Comment to Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer.
    Int J Urol. 2022 Apr 2. doi: 10.1111/iju.14890.
    PubMed    


    March 2022
  12. KAMITANI N, Miyaji Y, Tamada T, Yoden E, et al
    Feasibility of magnetic resonance imaging-ultrasound guided high-dose-rate brachytherapy for localized prostate cancer: Preliminary results from a prospective study.
    Int J Urol. 2022 Mar 30. doi: 10.1111/iju.14880.
    PubMed     Abstract available


  13. SHIOTA M
    Editorial Comment to Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2022 Mar 16. doi: 10.1111/iju.14864.
    PubMed    


  14. UEMURA H, Arai G, Uemura H, Suzuki H, et al
    Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III
    Int J Urol. 2022 Mar 15. doi: 10.1111/iju.14843.
    PubMed     Abstract available


  15. SASAKI D, Hatakeyama S, Tanaka T, Okamoto T, et al
    Impact of body size on skin-related adverse events in advanced prostate cancer treated with apalutamide: A multicenter retrospective study.
    Int J Urol. 2022 Mar 13. doi: 10.1111/iju.14860.
    PubMed    


  16. NARITA T, Hatakeyama S, Ohyama C
    Editorial Comment to Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
    Int J Urol. 2022 Mar 1. doi: 10.1111/iju.14849.
    PubMed    


    February 2022
  17. QIAN Y, Liu X, Feng Y, Li X, et al
    Tenascin C regulates cancer cell glycolysis and tumor progression in prostate cancer.
    Int J Urol. 2022 Feb 25. doi: 10.1111/iju.14830.
    PubMed     Abstract available


  18. LEE W, Lim B, Kyung YS, Kim CS, et al
    Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
    Int J Urol. 2022 Feb 8. doi: 10.1111/iju.14799.
    PubMed     Abstract available


  19. TANAKA T, Hatakeyama S, Noro D, Togashi K, et al
    Effect of upfront combination therapy on the overall survival of patients with metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2022 Feb 7. doi: 10.1111/iju.14817.
    PubMed    


    January 2022
  20. YANG Y, Liu Z, Wang Q, Chang K, et al
    Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer.
    Int J Urol. 2022 Jan 31. doi: 10.1111/iju.14801.
    PubMed     Abstract available


  21. BLAS L, Shiota M, Nagakawa S, Tsukahara S, et al
    Validation of models predicting lymph node involvement probability in patients with prostate cancer.
    Int J Urol. 2022 Jan 31. doi: 10.1111/iju.14802.
    PubMed     Abstract available


  22. NAGUMO Y, Onozawa M, Kojima T, Terada N, et al
    Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
    Int J Urol. 2022 Jan 25. doi: 10.1111/iju.14793.
    PubMed     Abstract available


  23. MOROZUMI K, Mitsuzuka K, Narita S, Takahashi M, et al
    Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score >/=8.
    Int J Urol. 2022 Jan 18. doi: 10.1111/iju.14781.
    PubMed     Abstract available


  24. HASEGAWA M, Yamada K, Shigeta K, Yuzuriha S, et al
    How long should urologists observe patients with prostate cancer after radical prostatectomy? Weibull analysis.
    Int J Urol. 2022 Jan 4. doi: 10.1111/iju.14774.
    PubMed     Abstract available


  25. YAMASHITA S, Kawabata H, Deguchi R, Ueda Y, et al
    Myosteatosis as a novel predictor of urinary incontinence after robot-assisted radical prostatectomy.
    Int J Urol. 2022;29:34-40.
    PubMed     Abstract available


    December 2021
  26. TAKAHARA K, Naiki T, Ito T, Nakane K, et al
    Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate.
    Int J Urol. 2021 Dec 4. doi: 10.1111/iju.14754.
    PubMed     Abstract available


    November 2021
  27. WURNSCHIMMEL C, Wenzel M, Chierigo F, Simone Flammia R, et al
    Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Nov 17. doi: 10.1111/iju.14743.
    PubMed    


  28. OWARI T, Tanaka N, Nakai Y, Miyake M, et al
    Impact of neoadjuvant androgen deprivation therapy on postimplant prostate D90 and prostate volume after low-dose-rate brachytherapy for localized prostate cancer.
    Int J Urol. 2021 Nov 11. doi: 10.1111/iju.14738.
    PubMed     Abstract available


  29. SO WZ, Wang Z, Tiong HY
    Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Nov 5. doi: 10.1111/iju.14741.
    PubMed    


    October 2021
  30. YUASA T
    Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
    Int J Urol. 2021 Oct 6. doi: 10.1111/iju.14725.
    PubMed    


  31. AKAKURA K
    Editorial Comment to External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Oct 4. doi: 10.1111/iju.14723.
    PubMed    


  32. YAMAMOTO S
    Editorial Comment to Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
    Int J Urol. 2021;28:1045-1046.
    PubMed    


  33. FUKUNAGA A, Maejima A, Shinoda Y, Matsui Y, et al
    Prognostic implication of staging of seminal vesicle invasion in patients with prostatic adenocarcinoma after prostatectomy.
    Int J Urol. 2021;28:1039-1045.
    PubMed     Abstract available


  34. TEO XL, Lim SK
    Targeting the vessels first: A modified surgical technique for prostatic paraganglioma.
    Int J Urol. 2021;28:1073-1074.
    PubMed    


    September 2021
  35. WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
    External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients.
    Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14701.
    PubMed     Abstract available


  36. SHIOTA M, Blas L, Kobayashi S, Matsumoto T, et al
    Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer.
    Int J Urol. 2021 Sep 22. doi: 10.1111/iju.14702.
    PubMed     Abstract available


  37. KADONO Y
    Editorial Comment to Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
    Int J Urol. 2021 Sep 8. doi: 10.1111/iju.14690.
    PubMed    


  38. COLARIETI A, Thiruchelvam N, Barrett T
    Evaluation of image-based prognostic parameters of post-prostatectomy urinary incontinence: A literature review.
    Int J Urol. 2021;28:890-897.
    PubMed     Abstract available


    August 2021
  39. MAESAKA F, Tanaka N, Nakai Y, Asakawa I, et al
    Comparison of disease-specific quality of life in prostate cancer patients treated with low-dose-rate brachytherapy: A randomized controlled trial of silodosin versus naftopidil.
    Int J Urol. 2021 Aug 10. doi: 10.1111/iju.14667.
    PubMed     Abstract available


  40. NAKAI Y, Tanaka N, Fujii T, Miyake M, et al
    Trends in risk classification at diagnosis and choice of primary therapy for prostate cancer: An analysis of 10 839 patients from the Nara Urological Research and Treatment Group registry between 2004 and 2015.
    Int J Urol. 2021 Aug 5. doi: 10.1111/iju.14666.
    PubMed     Abstract available


    July 2021
  41. MIYAMOTO S, Goto K, Honda Y, Terada H, et al
    Tumor contact length of prostate cancer determined by a three-dimensional method on multiparametric magnetic resonance imaging predicts extraprostatic extension and biochemical recurrence.
    Int J Urol. 2021 Jul 5. doi: 10.1111/iju.14633.
    PubMed     Abstract available


  42. SHIGEMURA K, Fujisawa M
    Prevention and management of infectious complications in prostate biopsy: A review.
    Int J Urol. 2021;28:714-719.
    PubMed     Abstract available


    June 2021
  43. SUGIHARA T
    Editorial Comment to Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
    Int J Urol. 2021 Jun 24. doi: 10.1111/iju.14620.
    PubMed    


  44. NAKAJIMA K, Mizokami A, Matsuyama H, Ichikawa T, et al
    Prognosis of patients with prostate cancer and bone metastasis from the Japanese Prostatic Cancer Registry of Standard Hormonal and Chemotherapy Using Bone Scan Index cohort study.
    Int J Urol. 2021 Jun 19. doi: 10.1111/iju.14614.
    PubMed     Abstract available


  45. ANDELA CD, Matte R, Jazet IM, Zonneveld WC, et al
    Effect of androgen deprivation therapy on cognitive functioning in men with prostate cancer: A systematic review.
    Int J Urol. 2021 Jun 14. doi: 10.1111/iju.14596.
    PubMed     Abstract available


  46. KIMURA Y, Honda M, Teraoka S, Yumioka T, et al
    Impact of penile rehabilitation with phosphodiesterase-5 inhibitors on recovery of erectile function in patients undergoing robot-assisted radical prostatectomy: A propensity score-matched analysis.
    Int J Urol. 2021;28:637-642.
    PubMed     Abstract available


  47. TAGUCHI S, Morikawa T, Shibahara J, Fukuhara H, et al
    Prognostic significance of tertiary Gleason pattern in the contemporary era of Gleason grade grouping: A narrative review.
    Int J Urol. 2021;28:614-621.
    PubMed     Abstract available


    May 2021
  48. STOLZENBACH LF, Deuker M, Colla-Ruvolo C, Nocera L, et al
    Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study.
    Int J Urol. 2021 May 28. doi: 10.1111/iju.14586.
    PubMed     Abstract available


  49. CHIKAMATSU S, Shiota M, Onozawa M, Hinotsu S, et al
    Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-institutional Japan-wide database.
    Int J Urol. 2021 May 24. doi: 10.1111/iju.14605.
    PubMed     Abstract available


  50. INOUE T, Yoshimura K, Terada N, Tsukino H, et al
    Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study).
    Int J Urol. 2021 May 18. doi: 10.1111/iju.14590.
    PubMed     Abstract available


  51. WURNSCHIMMEL C, Wenzel M, Colla Ruvolo C, Nocera L, et al
    Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups.
    Int J Urol. 2021 May 15. doi: 10.1111/iju.14595.
    PubMed     Abstract available


  52. IGUCHI T, Kimura G, Fukasawa S, Suzuki H, et al
    Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
    Int J Urol. 2021 May 6. doi: 10.1111/iju.14568.
    PubMed     Abstract available


  53. CLAPS F, Ramirez-Backhaus M, Mir Maresma MC, Gomez-Ferrer A, et al
    Indocyanine green guidance improves the efficiency of extended pelvic lymph node dissection during laparoscopic radical prostatectomy.
    Int J Urol. 2021;28:566-572.
    PubMed     Abstract available


  54. MATTI B, Zargar-Shoshtari K
    Age-adjusted reference values for prostate-specific antigen in a multi-ethnic population.
    Int J Urol. 2021;28:578-583.
    PubMed     Abstract available


  55. LOW AW, Chen K, Tan YG, Ng TK, et al
    Ambulatory robot-assisted laparoscopic radical prostatectomy with extended recovery by total extraperitoneal approach.
    Int J Urol. 2021;28:561-565.
    PubMed     Abstract available


    April 2021
  56. YOSHIDA S, Fujii Y
    Editorial Comment to Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
    Int J Urol. 2021 Apr 22. doi: 10.1111/iju.14578.
    PubMed    


  57. AIZAWA R, Takayama K, Nakamura K, Ogata T, et al
    Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate-targeted treatment and metastasis-directed therapy.
    Int J Urol. 2021 Apr 2. doi: 10.1111/iju.14567.
    PubMed     Abstract available


  58. TATENUMA T, Makiyama K, Ito Y, Muraoka K, et al
    Correlation of urinary loss rate after catheter removal and long-term urinary continence after robot-assisted laparoscopic radical prostatectomy.
    Int J Urol. 2021;28:440-443.
    PubMed     Abstract available


  59. HAGA N, Miyazaki T, Tsubouchi K, Okabe Y, et al
    Comprehensive approach for preserving cavernous nerves and erectile function after radical prostatectomy in the era of robotic surgery.
    Int J Urol. 2021;28:360-368.
    PubMed     Abstract available


    March 2021
  60. YOSHIDA S, Takahara T, Arita Y, Sakaino S, et al
    Whole-body diffusion-weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond.
    Int J Urol. 2021 Mar 6. doi: 10.1111/iju.14497.
    PubMed     Abstract available


  61. HATAKEYAMA S, Ohyama C
    Editorial Comment to Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.
    Int J Urol. 2021 Mar 4. doi: 10.1111/iju.14539.
    PubMed    


    February 2021
  62. SHIOTA M, Sumikawa R, Onozawa M, Hinotsu S, et al
    Regional and facility disparities in androgen deprivation therapy for prostate cancer from a multi-institutional Japan-wide database.
    Int J Urol. 2021 Feb 24. doi: 10.1111/iju.14518.
    PubMed     Abstract available


  63. HAGA N, Miyazaki T, Tsubouchi K, Okabe Y, et al
    Editorial Comment to Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial.
    Int J Urol. 2021 Feb 7. doi: 10.1111/iju.14511.
    PubMed    


  64. MINAGAWA T, Oguchi T, Saitou T, Fukazawa A, et al
    Impact of low-dose tadalafil on adverse events after low-dose-rate brachytherapy for prostate cancer: A bi-center randomized open-label trial.
    Int J Urol. 2021 Feb 7. doi: 10.1111/iju.14487.
    PubMed     Abstract available


  65. KUSHWAHA B, Devi A, Maikhuri JP, Rajender S, et al
    Inflammation driven tumor-like signaling in prostatic epithelial cells by sexually transmitted Trichomonas vaginalis.
    Int J Urol. 2021;28:225-240.
    PubMed     Abstract available


    January 2021
  66. HASHIMOTO T
    Editorial Comment to Benefits and harms of the new prostate cancer grade grouping on the prediction of long-term oncological outcomes in patients after radical prostatectomy.
    Int J Urol. 2021 Jan 28. doi: 10.1111/iju.14514.
    PubMed    


  67. NAGATA M
    Editorial Comment from Dr Nagata to Diagnostic performance of prostate cancer antigen 3 and the Prostate Health Index in detecting overall and clinically significant prostate cancer in men at first biopsy: A meta-analysis.
    Int J Urol. 2021 Jan 16. doi: 10.1111/iju.14494.
    PubMed    


  68. MILONAS D, Muilwijk T, Venclovas Z, Devos G, et al
    Benefits and harms of the new prostate cancer grade grouping on the prediction of long-term oncological outcomes in patients after radical prostatectomy.
    Int J Urol. 2021 Jan 6. doi: 10.1111/iju.14471.
    PubMed     Abstract available


  69. FALAGARIO UG, Lantz A, Jambor I, Martini A, et al
    Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion.
    Int J Urol. 2021;28:47-52.
    PubMed     Abstract available


    December 2020
  70. URABE F
    Editorial Comment from Dr Urabe to Diagnostic performance of prostate cancer antigen 3 and the Prostate Health Index in detecting overall and clinically significant prostate cancer in men at first biopsy: A meta-analysis.
    Int J Urol. 2020 Dec 19. doi: 10.1111/iju.14467.
    PubMed    


  71. JIA W, Wu B, Shao Y, Cao X, et al
    Diagnostic performance of prostate cancer antigen 3 and the Prostate Health Index in detecting overall and clinically significant prostate cancer in men at first biopsy: A meta-analysis.
    Int J Urol. 2020 Dec 18. doi: 10.1111/iju.14464.
    PubMed     Abstract available


  72. SAKAMOTO S
    Editorial Comment to Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Int J Urol. 2020 Dec 16. doi: 10.1111/iju.14470.
    PubMed    


  73. UEMURA H, Arai G, Uemura H, Suzuki H, et al
    Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study.
    Int J Urol. 2020 Dec 8. doi: 10.1111/iju.14447.
    PubMed     Abstract available


    November 2020
  74. KATO M, Sasaki T, Inoue T
    Current experimental human tissue-derived models for prostate cancer research.
    Int J Urol. 2020 Nov 27. doi: 10.1111/iju.14441.
    PubMed     Abstract available


  75. SHIRAISHI K
    Editorial Comment to Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems.
    Int J Urol. 2020 Nov 24. doi: 10.1111/iju.14446.
    PubMed    


  76. YOSHIDA S, Takahara T, Yokoyama M, Matsuoka Y, et al
    Can progressive site-directed therapy prolong the efficacy of subsequent androgen receptor axis-targeted drugs in oligometastatic castration-resistant prostate cancer?
    Int J Urol. 2020 Nov 2. doi: 10.1111/iju.14421.
    PubMed    


  77. MORITA M
    Editorial Comment to Coverage of the external prostatic region by the hybrid method compared with the conventional method of prostate low-dose-rate brachytherapy: A randomized controlled study.
    Int J Urol. 2020;27:1017-1018.
    PubMed    


    October 2020
  78. SUGIURA M, Sato H, Kanesaka M, Imamura Y, et al
    Epigenetic modifications in prostate cancer.
    Int J Urol. 2020 Oct 27. doi: 10.1111/iju.14406.
    PubMed     Abstract available


  79. MATSUOKA Y, Uehara S, Yoshida S, Tanaka H, et al
    Three-dimensional analysis of systematic biopsy-derived prostate cancer upgrading over targeted biopsy: Potential of target margin and surrounding region sampling using magnetic resonance-ultrasound image fusion systems.
    Int J Urol. 2020 Oct 27. doi: 10.1111/iju.14410.
    PubMed    


  80. NISHIMOTO M, Fujita K, Minami T, Yoshimura K, et al
    Editorial Comment to Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Int J Urol. 2020 Oct 17. doi: 10.1111/iju.14386.
    PubMed    


  81. HATAKEYAMA S, Ohyama C
    Response to Re: Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Oct 12. doi: 10.1111/iju.14399.
    PubMed    


  82. IWAMURA H, Hatakeyama S, Narita S, Arai Y, et al
    Prognosis of metastatic castration-resistant prostate cancer in the era of the second-generation androgen receptor-targeted agents: A retrospective multicenter study.
    Int J Urol. 2020 Oct 8. doi: 10.1111/iju.14392.
    PubMed    


  83. TAY KJ
    Editorial Comment from Dr Tay to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020;27:891-892.
    PubMed    


    September 2020
  84. SHIOTA M, Machidori A, Abe T, Monji K, et al
    Impact of antiandrogen withdrawal syndrome in castration-resistant prostate cancer patients treated with abiraterone or enzalutamide.
    Int J Urol. 2020 Sep 15. doi: 10.1111/iju.14366.
    PubMed     Abstract available


  85. SUGIMURA R, Kawahara T, Uemura H
    Re: Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Sep 13. doi: 10.1111/iju.14371.
    PubMed    


  86. SHIGETA K, Kikuchi E, Matsushima M, Ogihara K, et al
    Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy.
    Int J Urol. 2020 Sep 6. doi: 10.1111/iju.14358.
    PubMed     Abstract available


    August 2020
  87. KANEKO M, Yip W, Abreu AL
    Editorial Comment from Dr Kaneko et al. to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 29. doi: 10.1111/iju.14362.
    PubMed    


  88. SHOJI S
    Editorial Comment from Dr Shoji to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 29. doi: 10.1111/iju.14353.
    PubMed    


  89. KAWAHARA T
    Editorial Comment to Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.
    Int J Urol. 2020 Aug 8. doi: 10.1111/iju.14346.
    PubMed    


  90. AYDIN AM, Gage K, Dhillon J, Cheriyan SK, et al
    Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 6. doi: 10.1111/iju.14321.
    PubMed     Abstract available


    July 2020
  91. IPPOLITO D, Querques G, Pecorelli A, Perugini G, et al
    Diagnostic accuracy of multiparametric magnetic resonance imaging combined with clinical parameters in the detection of clinically significant prostate cancer: A novel diagnostic model.
    Int J Urol. 2020 Jul 25. doi: 10.1111/iju.14316.
    PubMed     Abstract available


  92. MARTELL K
    Editorial Comment to High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Int J Urol. 2020 Jul 22. doi: 10.1111/iju.14328.
    PubMed    


  93. VAN POPPEL H, Abrahamsson PA
    Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.
    Int J Urol. 2020 Jul 13. doi: 10.1111/iju.14303.
    PubMed     Abstract available


  94. KASAHARA T, Ishizaki F, Kazama A, Yuki E, et al
    High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer.
    Int J Urol. 2020 Jul 7. doi: 10.1111/iju.14305.
    PubMed     Abstract available


  95. HAGHSHENO MA, Hammarsten J, Peeker R, Behre CJ, et al
    Men with type 2 diabetes mellitus have a lower detection rate of prostate cancer.
    Int J Urol. 2020 Jul 6. doi: 10.1111/iju.14304.
    PubMed    


    June 2020
  96. NAKAI Y, Tanaka N, Asakawa I, Anai S, et al
    Biochemical control of the combination of cyclooxygenase-2 inhibitor and (125) I-brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial.
    Int J Urol. 2020 Jun 26. doi: 10.1111/iju.14294.
    PubMed     Abstract available


  97. MOMOTA M, Hatakeyama S, Soma O, Tanaka T, et al
    Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Jun 4. doi: 10.1111/iju.14256.
    PubMed     Abstract available


    May 2020
  98. KATO M
    Editorial Comment to Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2020 May 30. doi: 10.1111/iju.14278.
    PubMed    


  99. HATAKEYAMA S, Narita S, Takahashi M, Sakurai T, et al
    Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Int J Urol. 2020 May 16. doi: 10.1111/iju.14258.
    PubMed     Abstract available


    April 2020
  100. YOSHIDA S, Takahara T, Arita Y, Toda K, et al
    Patterns of failure after progressive site-directed therapy in oligo-progressive castration-resistant prostate cancer.
    Int J Urol. 2020 Apr 14. doi: 10.1111/iju.14249.
    PubMed    


    March 2020
  101. KAWAHARA T, Miyoshi Y, Uemura H
    Re: Current treatment strategies for advanced prostate cancer.
    Int J Urol. 2020 Mar 31. doi: 10.1111/iju.14237.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: